Cargando…
Biomarker-guided trials: Challenges in practice
Biomarker-guided trials have drawn considerable attention as they promise to lead to improvements in the benefit-risk ratio of treatments and enhanced opportunities for drug development. A variety of such designs have been proposed in the literature, many of which have been adopted in practice. Impl...
Autores principales: | Antoniou, M., Kolamunnage-Dona, R., Wason, J., Bathia, R., Billingham, C., Bliss, J.M., Brown, L.C., Gillman, A., Paul, J., Jorgensen, A.L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6879976/ https://www.ncbi.nlm.nih.gov/pubmed/31788574 http://dx.doi.org/10.1016/j.conctc.2019.100493 |
Ejemplares similares
-
Evaluating statistical characteristics of biomarker-guided trial designs
por: Antoniou, Miranta, et al.
Publicado: (2015) -
Biomarker-Guided Adaptive Trial Designs in Phase II and Phase III: A Methodological Review
por: Antoniou, Miranta, et al.
Publicado: (2016) -
Biomarker-Guided Non-Adaptive Trial Designs in Phase II and Phase III: A Methodological Review
por: Antoniou, Miranta, et al.
Publicado: (2017) -
Correction: Antoniou, M.; et al. Biomarker-Guided Non-Adaptive Trial Designs in Phase II and Phase III: A Methodological Review. J. Pers. Med. 2017, 7, 1
por: Antoniou, Miranta, et al.
Publicado: (2018) -
Correction: Antoniou, M.; et al. Fixed and Adaptive Parallel Subgroup-Specific Design for Survival Outcomes: Power and Sample Size. J. Pers. Med. 2017, 7, 19
por: Antoniou, Miranta, et al.
Publicado: (2018)